|
AKRO | Akero Therapeutics, Inc. |
|
|
AKRO | Akero Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.31 |
| Leverage | 4.77% |
| Market Cap | $ 3.1B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -292.0m |
| Margin | 0.00% |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, is dedicated to developing medications designed to restore metabolic balance and improve overall health. The company is headquartered in South San Francisco, California.